Clinical Study
Efficacy of Goshajinkigan for Oxaliplatin-Induced Peripheral Neuropathy in Colorectal Cancer Patients
Table 4
Adverse events of grades 3 and 4 observed in the GJG and non-GJG groups receiving oxaliplatin-based chemotherapy.
| ā | GJG group N = 29 | Non-GJG group N = 44 |
| General fatigue | 0 | 4/44, 9.0% | Allergic reaction | 0 | 1/44, 2.2% | Oral mucositis | 2/29, 6.9% | 1/44, 2.2% | Disorder of blood | 3/29, 10.3% | 4/44, 9.0% | Infection | 1/29, 3.4% | 4/44, 9.0% | Nausea and vomiting | 4/29, 13.7% | 7/44, 15.9% | Diarrhea | 2/29, 6.9% | 3/44, 6.8% | Hand-foot syndrome | 0 | 1/44, 2.2% | Pain | 1/29, 3.4% | 2/44, 4.5% | Peripheral neuropathy | 2/29, 6.9% | 15/44, 34.0% |
|
|